Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: Possible significance of CRTC1–MAML2 oncogene

O’Neill, Iain D.

doi:10.1016/j.lungcan.2009.01.003

Cited by 42 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR is not the only target of gefitinib. Some clinicians [17] assumed that t(11;19) and associated fusion CRTC1-MAML2 may be the targets of EGFR TKI therapy. However, further studies need to be conducted to clarify the mechanism of EGFR TKIs.…”

Section: Discussionmentioning

confidence: 99%

Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases

Jiang

et al. 2012

World J Surg Onc

View full text Add to dashboard Cite

BackgroundThe optimal treatment for pulmonary mucoepidermoid carcinoma (MEC), a rare type of tumor, has not been established yet. This study analyzed the survival of pulmonary MEC patients and attempted to find clues for optimal treatment.MethodsA total of 21 patients with pulmonary MEC from November 2004 to January 2011 were included in the investigation. Immunohistochemistry, epidermal growth factor receptor (EGFR) mutation, and survival were retrospectively studied.ResultsAmong the 21 pulmonary MEC patients, 17 were diagnosed with low-grade malignancy and 4 with high-grade malignancy through pathological examination. The prognosis was found to be poor in the presence of lymph nodes. The expression rates of EGFR and HER2 were 28.6% and 0%, respectively, which correlated with neither grade nor prognosis. The mutation rate of EGFR was 0. Log-rank test results indicated that age, grade, lymph node metastasis, and tumor-node-metastasis stage were prognostic factors.ConclusionAge, grade, lymph node metastasis and tumor-node-metastasis stage correlate with the survival of pulmonary MEC patients.Trial registrationThis study was approved and registered by the Ethics Committee of Zhongshan Hospital. Written informed consent was obtained from all participants prior to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases

Jiang

et al. 2012

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…However, it is possible that other genetic alterations may activate the EGFR signalling pathway in the absence of intrinsic gene mutations. For example, disease in patients with mucoepidermoid carcinomas (MECs) of the salivary and bronchial glands with wild-type EGFR has responded to gefitinib 28,29 , and MEC cell lines are sensitive to EGFR TKIs in vitro 30 . As MECs harbour a recurrent mucoepidermoid carcinoma translocated 1 ( MECT1 ) – mastermind-like 2 ( MAML2 ) fusion 31 that induces expression of the EGFR ligand amphiregulin 30 , one possibility is that gefitinib sensitivity is mediated by the action of the aberrant fusion protein.…”

Section: First-generation Anti-egfr Therapymentioning

confidence: 99%

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

2010

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.

show abstract

“…Ordinary MC has been shown to contain characteristic fusion genes, such as CRTC1‐MAML2 , CRTC2‐MAML2 and CRTC3‐MAML2 , which are associated with several clinicopathologic features, including patient's age and disease prognosis . These fusion genes have been identified in an unusual histological variant of MC and in tumors developing in non‐salivary gland sites . However, none of the aforementioned fusion‐ gene transcripts was indentified in our case.…”

Section: Discussionmentioning

confidence: 63%

Sclerosing mucoepidermoid carcinoma with eosinophilia of the salivary gland: Case report and review of the literature

Tasaki

Matsuyama

Tabata

et al. 2013

Pathology International

View full text Add to dashboard Cite

Sclerosing mucoepidermoid carcinoma with eosinophilia (SMCE) of the salivary gland is a rare variant of mucoepidermoid carcinoma. We report a case of SMCE in the right submandibular gland of a 79-year-old man. Fine needle aspiration cytology revealed cohesive clusters of atypical squamous epithelial cells admixed with cells containing intracytoplasmic mucin and eosinophils. Histologically, the tumor was composed of epithelial nests with keratinizing cells occasionally present at the center, as well as peripherally located atypical basaloid cells, and some mucin-containing cells embedded in a fibrosclerotic stroma, which were accompanied by a prominent lymphoplasmacytic and eosinophilic infiltrate. Inflammatory infiltrate and stromal fibrosclerosis also were seen in the non-neoplastic salivary gland tissue adjacent to the tumor. Immunohistochemically, many plasma cells were IgG4-positive. The postoperative serum IgG4 level was elevated. Our reverse transcription-polymerase chain reaction using formalin-fixed, paraffin-embedded tumor tissue failed to detect any fusion-gene transcripts which are specifically identified in ordinary mucoepidermoid carcinoma. The findings of the present case suggest that this rare type of salivary gland carcinoma may be associated with a chronic inflammatory condition such as IgG4-related sclerosing disease. Only 23 cases of sclerosing mucoepidermoid carcinoma with or without eosinophilic infiltratie have been reported to date in such an anatomical location.

show abstract

Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: Possible significance of CRTC1–MAML2 oncogene

Cited by 42 publications

References 11 publications

Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases

Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Sclerosing mucoepidermoid carcinoma with eosinophilia of the salivary gland: Case report and review of the literature

Contact Info

Product

Resources

About